Jefferies Initiates Coverage On Nurix Therapeutics with Buy Rating, Announces Price Target of $41
Portfolio Pulse from Benzinga Newsdesk
Jefferies has initiated coverage on Nurix Therapeutics with a Buy rating and set a price target of $41.
October 11, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has initiated coverage on Nurix Therapeutics with a Buy rating and a price target of $41, indicating a positive outlook for the stock.
The initiation of coverage by Jefferies with a Buy rating and a specific price target of $41 suggests a positive sentiment towards Nurix Therapeutics. This is likely to influence investor perception and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100